Related Experiment Videos
Streptococcal pharyngitis. Placebo-controlled double-blind evaluation of clinical response to penicillin therapy
Insights
Early penicillin treatment for streptococcal pharyngitis in children significantly improves clinical outcomes. Penicillin therapy shortened illness duration and reduced symptom severity compared to placebo in this randomized trial.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Streptococcal pharyngitis is a common childhood illness.
- Prompt diagnosis and treatment are crucial to prevent complications.
Purpose of the Study:
- To evaluate the clinical efficacy of early penicillin treatment for streptococcal pharyngitis in children.
- To assess the impact of penicillin on symptom resolution and fever reduction.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 44 children diagnosed with streptococcal pharyngitis.
- Participants received either oral penicillin or placebo for 72 hours.
- Clinical assessments, including temperature and symptom severity, were recorded at multiple time points.
Main Results:
- Throat cultures confirmed group A beta-hemolytic streptococci in 59% of participants.
- Children treated with penicillin showed statistically significant clinical improvement compared to the placebo group.
- Fever and symptom severity were significantly reduced in the penicillin group within 48 hours.
Conclusions:
- Early penicillin administration significantly alters the acute clinical course of streptococcal pharyngitis in children.
- Penicillin treatment leads to faster symptom resolution and reduced fever.
- This study supports the use of penicillin for managing streptococcal pharyngitis in pediatric patients.
Abstract:
Forty-four children with a clinical diagnosis of streptococcal pharyngitis had throat cultures performed at the initial evaluation and were assigned by randomization to receive either oral penicillin or a placebo for 72 hours. The treating physician, who remained blind to the treatment regimen, recorded the child's temperature and assessed the presence and severity of other signs and symptoms initially and at 24, 48, and 72 hours. The throat culture was positive for group A beta-hemolytic streptococci in 26 (59%) of the initial study group, and most of these children developed a fourfold or greater titer rise in antistreptococcal antibodies in their serum, confirming the diagnosis of streptococcal pharyngitis. Statistically significant clinical improvement was observed in the group of 11 children who were later shown to have been taking penicillin compared with the group of 15 who had taken the placebo. Significant differences in the presence and degree of fever and severity of symptoms persisted in the placebo-treated group for 48 hours. We conclude that early penicillin treatment of children with streptococcal pharyngitis significantly alters the acute clinical course of the disease.